The Event has Ended
The NHS Oncology Conference 2022 London
08:00 am
06 Oct, 2022
15 Hatfields Conference Centre, London SE1 8DJ
The NHS Oncology Conference 2022 London
08:00 am
06 Oct, 2022
15 Hatfields Conference Centre, London SE1 8DJ
The NHS Oncology Conference 2022 London
The NHS Oncology Conference provides a high-value and peers focused platform for NHS Oncology and Cancer specialists to share practical insights and best practices from across the UK. Our physical events offer a unique opportunity to meet with key sector stakeholders in an informal and relaxed atmosphere, this provides an ideal chance to discuss strategic change and learn from some of the most well-respected public sector professionals in the country, all while soaking up the lovely atmosphere our venues and audience provide.
The Covid pandemic caused a sharp increase in waiting times and backlogs in a healthcare system that was already operating extremely close to its maximum capacity. By September 2021, it’s estimated there were 5.83 million patients on the waiting list for elective care, 1.95 million of those patients had been waiting for more than 18 weeks, including 301,000 waiting for more than a year.
To try and reduce further crisis NHS England set up a national Cancer Recovery Taskforce, headed up by Professor Peter Johnson, National Clinical Director for Cancer, and includes representatives from cancer charities, royal colleges, national teams and the NHS Cancer Programme’s Patient and Public Voices (PPV) Forum
The task force’s focus is the recovery of cancer services and it reports to the National Cancer Board which oversees the delivery of the NHS Long Term Plan ambitions for cancer – to diagnose 75% of cancers at stage 1 or 2, and for 55,000 more people to survive for five years or more by 2028.
The task force’s roles are to:
- Review progress against the aims of the recovery plan monthly, reporting to the
National Cancer Board.
- Identify any requirements for the successful recovery of cancer services that are
the responsibility of stakeholders outside the NHS Cancer Programme (eg public
awareness, cancer screening, infection control measures)
- Understand and represent the needs of patients and their families, and NHS staff,
and engage with the wider cancer community on the national delivery of the
the recovery plan and its progress.
- Share practical suggestions about what the wider cancer community can do to
support recovery.
Our upcoming conference aims to provide delegates with clear direction on the national strategy, which has been set in motion to help reduce the pressure on NHS Oncology services, and how it plans to support the people working in our NHS – the GPs, nurses, oncologists, radiographers and radiologists to name but a few – who will deliver these improvements at a local level.
Join us at The NHS Oncology Conference 2022 as we explore these new areas of best practice, network with peers and share insights across a short but high-value conference.
Research sources: NHS England and improvement, Cancer Research UK, The Guardian, Health Education England
AstraZeneca has provided a sponsorship grant towards this independent programme
The NHS Oncology Conference 2021: Innovating Through Backlogs Overview:
- 51% of Delegates would recommend Convenzis to their Colleagues.
- 53% of Delegates rated our speakers as either Good or Excellent.
- 69% of Attendees were at Senior Management Level or above.
- 97% of Delegates are interested in attending the next event.
- 30% of Delegates would like to receive more information from all Sponsors.
The NHS Oncology Conference 2022 London Key Subjects
The key topics to be discussed are:
- Patient-centred approaches
- Innovation in AI
- Screening
- Photobiomodulation Therapy
- Personalised care
- Rehabilitation
- Whole Genome Sequencing in Paediatric Oncology
Who will Attend
- Advanced Registered Practice Nurse
- Anaesthesiologists
- Case Managers
- Chief Technology Officers
- Clinical Nurse Specialists
- Directors/Heads of Oncology
- Clinical Directors/Heads/Leads
- Medical Directors/Heads
- Medical Imaging Directors/Heads/Managers
- Pain Specialists
- Palliative Care Specialists
- Pathologists
- Paediatric Oncologists
- Radiologists
- Surgical Oncologists
- Urologists
- Pharmacologists
Speakers
Catherine Lloyd Bennett
Macmillan Clinical Nurse Specialist
Chris Elkin
Head of Healthcare
Dr Heather Wilkes
GP, National RDC Clinical Lead
Sponsors & Partners
The Agenda
08:00
Registration, Networking & Breakfast
Registration, Networking & Breakfast
09:00
Chairs Opening Address
Dr Anthony Cunliffe
National Lead Medical Adviser and the Clinical Adviser for London at Macmillan Cancer Support
Joint Clinical Director for the South East London Cancer Alliance
Chairs Opening Address
09:05
Creating world class cancer services through faster, earlier diagnosis and personalised care and treatment (Confirmed)
Professor Peter Johnson
National Clinical Director for Cancer
NHS England
A look at the priorities for the NHS Cancer Programme, including:
- Rising to the challenge of record high levels of cancer referrals through expanding capacity, improving pathways and improving faster diagnosis
- Accelerating progress on our aim to diagnose three quarters of cancers at stage 1 or 2 by 2028
Personalised care and putting excellent patient experience at the heart of everything we do.
09:25
RDC#2 – piloting site-specific pathways, new roles & new sites (Confirmed)
Dr Heather Wilkes
GP, National RDC Clinical Lead
Swansea Bay University Health Board
Catherine Lloyd Bennett
Macmillan Clinical Nurse Specialist
Wales Cancer Initiative
Vague Symptom RDCs were pioneered in Wales, the first opening in 2017 with now proven patient, staff & service benefits. The core patient-centred holistic approach is now being utilised to develop cancer site-specific services and innovative staff development, with joint support and funding from SBUHB & MCI.
09:45
Personalised Care for people living with and beyond cancer (Confirmed)
Leah Morgan
Cancer Survivorship Improvement Facilitator
Shrewsbury and Telford Hospitals NHS Trust
This presentation looks at how the Personalised Care NHS Long Term Plan is evolving to ensure people have more choice and control over the way their care is planned and delivered. This ensures that it is based on ‘what matters’ to them and their individual strengths and needs.
There are several components of personalised care that work together to deliver an overall holistic approach for the patient throughout their treatment and beyond; this includes building strong relationships with Social Prescribing and other community-based support. Personalised care recognises that, for many people, their needs arise from circumstances beyond the purely medical, and by introducing connections to services and organisations in their communities, this will enable the person living with cancer to access support and build resilience at a time that suits them.
10:05
Early diagnosis and screening: Reaching for the “Gold Standard”
Gero Struebbe
Franchise Head, UK Sales & Marketing for lung cancer & immune-oncology
AstraZeneca
Jane Derbyshire
Project Manager, Targeted Lung Health Check Programme
RM Partners
Dr Ley Chan
Clinical Research Fellow, Targeted Lung Health Check Programme
RM Partners
Main Sponsor - AstraZeneca
AstraZeneca has provided a sponsorship grant towards this independent programme
10:25
Q&A Panel
Q&A Panel
10:40
Morning Break, Networking & Refreshments
Morning Break, Networking & Refreshments
11:40
Chairs Morning Reflections
Dr Anthony Cunliffe
National Lead Medical Adviser and the Clinical Adviser for London at Macmillan Cancer Support
Joint Clinical Director for the South East London Cancer Alliance
Chairs Morning Reflections
11:45
Reducing incidence and severity of Oral Mucositis with Photobiomodulation
James Carroll
CEO
THOR Photomedicine Ltd
Case Study
12:15
Clinical utility of WGS for children with cancer (Confirmed)
Sam Behjati
Group Leader
Wellcome Sanger Institute
Whole-genome sequencing (WGS) is now routinely available to every child in England diagnosed with cancer. Here, I present our experience of utilising WGS in children with cancer in terms of improving patient management.
12:35
First Intraoperative Radiation Therapy Centre in Africa: First 2 Years in Operation, Including COVID-19 Experience
Prof Carol-Ann Benn
Head of the Breast Unit Netcare Breast Care Centre of Excellence at the Milpark Hospital, Johannesburg, and of Helen Joseph Hospital
Breast Care Centre of Excellence; Breast Health Foundation
Case Study - Zeiss
First Intraoperative Radiation Therapy Centre in Africa: First 2 Years in Operation, Including COVID-19 Experience
There is a global shortage of radiation therapy service centres. TARGIT–intraoperative radiation therapy (IORT) may offer a viable alternative to improve radiation treatment efficiency and alleviate hospital patient loads. The Breast Care Unit in Johannesburg became the first facility in Africa to offer TARGIT-IORT, and the purpose of this presentation is to highlight our experience.
12:55
Implementing the cancer rehabilitation model at scale to improve patient and system outcomes (Confirmed)
Catherine Neck
Clinical Services Programme Lead: Cancer and Long-Term Conditions
NHS South Central and West Commissioning Support Unit
This presentation discusses how the outcomes from the Greater Manchester Prehab4Cancer programme can be replicated across other cancer sites and treatments to benefit patients and NHS systems. It highlights the need for rehabilitation and rehabilitation to become a standard of care for people with cancer
13:15
Q&A Panel
Q&A Panel
13:30
Networking and Lunch
Networking and Lunch
14:15
Chairs Afternoon Address
Dr Anthony Cunliffe
National Lead Medical Adviser and the Clinical Adviser for London at Macmillan Cancer Support
Joint Clinical Director for the South East London Cancer Alliance
Chairs Afternoon Address
14:20
Case Study - Piota Healthcare Apps (Confirmed)
Chris Elkin
Head of Healthcare
Piota Healthcare Apps
Case Study
Piota is a leading provider of Healthcare Apps to the NHS.
During this session we will demonstrate how Healthcare Teams like yours are using the Piota App platform to:
- Improve the patient experience
- Increase staff wellbeing & engagement
- Save valuable clinical time by making operational information readily accessible
14:40
Artificial intelligence in cancer screening and detection (Confirmed)
JD Blackwood
CTO and NHS National Programme Manager
iCAIRD
The Industrial Centre for Artificial Intelligence Research in Digital Diagnostics is the UK’s largest dedicated healthcare AI programme. Based in Scotland and funded by Innovate UK, this £20m+ national programme operates over 35 research and AI evaluation projects with over 30 global partners, including NHS Scotland.
Over a third of those projects focus upon cancer screening and detection in radiology and pathology imaging. Together, we’ll examine how the technology examined by iCAIRD could be used within oncology pathways and discuss how we can adopt those innovations within the NHS, quickly and at scale.
15:00
Targeted Intraoperative radiotherapy – better for eligible breast cancer patients than other forms of radiotherapy – data from the TARGIT-A trial (Confirmed)
Professor Jayant S Vaidya
Professor of Surgery and Oncology
University College London
Rather than the usual post-operative course of radiotherapy given daily over several days, risk-adapted single-dose targeted intraoperative radiotherapy (TARGIT-IORT) given during lumpectomy for breast cancer, provides the patient with effective and safer, individualised form of radiotherapy.
The large international randomised TARGIT-A trial has confirmed that TARGIT-IORT produces long-term cancer outcome as good as whole breast radiotherapy in all invasive ductal cancer subtypes, and reduces deaths from other causes. There is an improved overall survival in grade 1 and 2 cancers and no detriment in grade 3 cancers. TARGIT-IORT leads to less pain, superior cosmetic results, improved quality of life and is saves scarce resources. Unlike the poor prognosis of patients who relapse locally after whole breast radiotherapy, a local relapse after TARGIT-IORT continues to remain excellent, and as good as without a local relapse.
For more information see https://targit.org.uk
15:20
Q&A Panel
Q&A Panel
15:40
End of Day
End of Day
